Categories: News

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.

About BiomX

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+97250-6977228
anatp@biomx.com 

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
jmullaly@lifesciadvisors.com 

Source: BiomX Inc

Staff

Recent Posts

Epic UGM 2025 Survival Guide: Insider Tips for Vendors, Storytellers, and Market Watchers

Black Book Research Marks Its 12th Year on the Ground in Verona with Independent, Vendor-Agnostic…

16 hours ago

rYojbaba Co., Ltd. Announces Closing of $5 Million Initial Public Offering of Japanese Common Shares

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or…

19 hours ago

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug…

19 hours ago

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No WarrantsLos Angeles, CA, Aug.…

19 hours ago

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc., a clinical-stage biopharmaceutical…

19 hours ago